Dr. Hammers on Next Steps with Immunotherapy in RCC

Hans J. Hammers, MD, PhD
Published: Wednesday, Aug 23, 2017



Hans J. Hammers, MD, PhD, associate professor, Internal Medicine, UT Southwestern Medical Center, discusses the next steps with immunotherapy for patients with renal cell carcinoma (RCC).

Data are still needed to determine the response of nivolumab (Opdivo) in certain subsets of patients, states Hammers. If there is a signal of clinical activity, it might be studied in combination with other regimens for this patient population.



Hans J. Hammers, MD, PhD, associate professor, Internal Medicine, UT Southwestern Medical Center, discusses the next steps with immunotherapy for patients with renal cell carcinoma (RCC).

Data are still needed to determine the response of nivolumab (Opdivo) in certain subsets of patients, states Hammers. If there is a signal of clinical activity, it might be studied in combination with other regimens for this patient population.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Publication Bottom Border
Border Publication
x